Why is Eli Lilly Betting Big on Orforglipron with a $1.5 Billion Inventory

Related Articles

Why is Eli Lilly Betting on Shingles Vaccines

3 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

5 months ago

Is McDonald's Betting Big on Premium with the Big Arch Burger

6 months ago

What's Driving the Bearish Options Activity in Eli Lilly

5 months ago

Category

You may also like

Stock News•1 week ago

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

Eli Lilly's broad weight-loss pipeline could sustain its market lead and support excellent medium-term financial results, as the company targets multiple patient types with new products.

LLY

Share

Stock News•4 weeks ago

Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal

Eli Lilly and Resilience will invest $750 million to expand pharmaceutical production in Cincinnati, adding Lilly's KwikPen manufacturing capacity for diabetes and obesity drugs.

LLY

Share

Stock News•1 months ago

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?

Pfizer is developing a long-acting GLP-1 drug for the weight-loss market, aiming to compete with Eli Lilly and Novo Nordisk. The company's update suggests it could produce a blockbuster like Lipitor.

PFE

Share

Stock News•1 months ago

Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio — It's Missing the $1 Trillion Opportunity

Eli Lilly's GLP-1 portfolio is attracting Wall Street bets, but the market may be overlooking a broader $1 trillion opportunity at the intersection of biology and AI.

GLP

Share